Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock Position Boosted by Chase Investment Counsel Corp

Chase Investment Counsel Corp grew its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 45.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,000 shares of the company’s stock after buying an additional 9,000 shares during the quarter. Chase Investment Counsel Corp’s holdings in Amphastar Pharmaceuticals were worth $1,407,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its stake in shares of Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after acquiring an additional 273 shares during the period. Innealta Capital LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $55,000. Blue Trust Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares in the last quarter. Asset Management One Co. Ltd. acquired a new stake in Amphastar Pharmaceuticals during the third quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after buying an additional 301 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Down 1.8 %

Shares of Amphastar Pharmaceuticals stock opened at $47.71 on Wednesday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The company has a market cap of $2.29 billion, a P/E ratio of 15.90, a P/E/G ratio of 0.94 and a beta of 0.82. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a 50-day moving average price of $48.45 and a 200 day moving average price of $44.34.

Wall Street Analyst Weigh In

Several research analysts have issued reports on AMPH shares. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $63.00.

Insider Activity

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now owns 75,409 shares in the company, valued at approximately $3,504,256.23. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO William J. Peters sold 7,426 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,898,061.15. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 19,640 shares of company stock worth $990,722 in the last 90 days. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.